The seminal article by Douglas Hanahan and Robert Weinberg on the hallmarks of cancer is 10 years old this year and its contribution to how we see cancer has been substantial. But, in embracing this view, have we lost sight of what makes cancer cancer?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota
Clinical and Translational Medicine Open Access 27 August 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Giordano, A., De Falco, G., Rubin, E. & Rubin, R. in Rubin's Pathology: Clinicopathologic Foundations of Medicine (eds. Rubin, R. & Strayer, D. S.) (Wolters Kluwer, Lippincott Williams & Williams, Philadelphia, Baltimore, 2008).
Barnett, C. C. Jr et al. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 128, 973–983 (2000).
Favia, G., Lumachi, F., Basso, S. & D'Amico, D. F. Management of incidentally discovered adrenal masses and risk of malignancy. Surgery 128, 918–924 (2000).
Coleman, J. A. & Russo, P. Hereditary and familial kidney cancer. Curr. Opin. Urol. 19, 478–485 (2009).
Abouzeid, H., Schorderet, D. F., Balmer, A. & Munier, F. L. Germline mutations in retinoma patients: relevance to low-penetrance and low-expressivity molecular basis. Mol. Vis. 15, 771–777 (2009).
Huntington, M. K., Kruger, R. & Ohrt, D. W. Large, complex, benign cystic teratoma in an adolescent. J. Am. Board Fam Pract 15, 164–167 (2002).
Udapudi, D. G., Vasudeva, P., Srikantiah, R. & Virupakshappa, E. Massive benign phyllodes tumor. Breast J. 11, 521 (2005).
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Raica, M., Cimpean, A. M. & Ribatti, D. Angiogenesis in pre-malignant conditions. Eur. J. Cancer 45, 1924–1934 (2009).
Fleischer, R., Weston, G. C., Vollenhoven, B. J. & Rogers, P. A. Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract. Res. Clin. Obstet. Gynaecol. 22, 603–614 (2008).
Lee, K. L. & Peehl, D. M. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J. Urol. 172, 1784–1791 (2004).
Utermark, T., Kaempchen, K., Antoniadis, G. & Hanemann, C. O. Reduced apoptosis rates in human schwannomas. Brain Pathol. 15, 17–22 (2005).
Okolo, S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol. 22, 571–588 (2008).
Wanless, I. R. Benign liver tumors. Clin. Liver Dis. 6, 513–526 (2002).
Sozen, I. & Arici, A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet. Gynecol. Clin. North Am. 33, 41–58 (2006).
Jagannathan, J., Oskouian, R. J., Yeoh, H. K., Saulle, D. & Dumont, A. S. Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature. Skull Base 18, 173–187 (2008).
Hansen, M. R., Roehm, P. C., Chatterjee, P. & Green, S. H. Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation. Glia 53, 593–600 (2006).
Lucia, M. S. & Lambert, J. R. Growth factors in benign prostatic hyperplasia: basic science implications. Curr. Urol. Rep. 9, 272–278 (2008).
Henske, E. P. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosom. Cancer 38, 376–381 (2003).
Stoecklein, N. H. & Klein, C. A. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int. J. Cancer 126, 589–598 (2009).
Klein, C. A. Parallel progression of primary tumours and metastases. Nature Rev. Cancer 9, 302–312 (2009).
Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
Acknowledgements
I would like to thank D. Berman (Departments of Pathology, Oncology, and Urology at Johns Hopkins University, USA), T. Ried (Section of Cancer Genomics, National Cancer Institute, USA), D. Duelli (Department of Pathology, the Rosalind Franklin University, USA) and G. Parris (Center of Cancer Systems Biology, Tufts University, USA) for insightful comments.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Lazebnik, Y. What are the hallmarks of cancer?. Nat Rev Cancer 10, 232–233 (2010). https://doi.org/10.1038/nrc2827
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2827
This article is cited by
-
The hallmarks of cancer… in pituitary tumors?
Reviews in Endocrine and Metabolic Disorders (2023)
-
Redox balance and autophagy regulation in cancer progression and their therapeutic perspective
Medical Oncology (2022)
-
Chemerin reverses the malignant phenotype and induces differentiation of human hepatoma SMMC7721 cells
Archives of Pharmacal Research (2021)
-
Invasion and metastasis: the elusive hallmark of cancer
Oncogene (2020)
-
New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota
Clinical and Translational Medicine (2019)